In episode 164, Mike and James finally get to another PREMIUM episode and boy is it ever premium. We discuss the latest HDL raising drugs, ASA after a DVT, and a new meta-analysis of metformin. With our usual skill, alacrity and boyish charm we give all our premium listeners their monies worth with practice changing evidence.
1) Dalcetrapib (HDL raising) study stopped due to no benefit
Roche news release
2) Genetic HDL – no reduction in heart disease
3) WARFASA – Aspirin for Preventing the Recurrence of Venous Thromboembolism
N Engl J Med 2012;366:1959-67
4) A new metformin meta-analysis – is it good or bad?
PLoS Med 9(4): e1001204. doi:10.1371/journal.pmed.1001204